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Background: Biological agents such as tumor necrosis factor-α inhibitors are known to cause mycobacterium
infections. Here, we report a disseminated non-tuberculosis case caused by TNF-α inhibitor therapy and a probable
paradoxical response to antimycobacterial therapy.
Case presentation: A 68-year-old man with relapsing polychondritis was refractory to glucocorticoid therapy;
adalimumab was therefore administered in combination with oral glucocorticoids. Treatment with 40 mg of
adalimumab led to rapid improvement of his clinical manifestations. The administration of tacrolimus (1 mg) was
started as the dosage of oral glucocorticoids was tapered. However, the patient developed an intermittent high
fever and productive cough 15 months after starting adalimumab treatment. A chest computed tomography scan
revealed new granular shadows and multiple nodules in both lung fields with mediastinal lymphadenopathy,
and Mycobacterium intracellulare was isolated from 2 sputum samples; based on these findings, the patient was
diagnosed with non-tuberculosis mycobacteriosis. Tacrolimus treatment was discontinued and oral clarithromycin
(800 mg/day), rifampicin (450 mg/day), and ethambutol (750 mg/day) treatment was initiated. However, his
condition continued to deteriorate despite 4 months of treatment; moreover, paravertebral and subcutaneous
abscesses developed and increased the size of the mediastinal lymphadenopathy. Biopsy of the mediastinal
lymphadenopathy and a subcutaneous abscess of the right posterior thigh indicated the presence of
Mycobacterium avium complex (MAC), and the diagnosis of disseminated non-tuberculosis mycobacteriosis was
confirmed. Despite 9 months of antimycobacterial therapy, the mediastinal lymphadenopathy and paravertebral
and subcutaneous abscesses had enlarged and additional subcutaneous abscesses had developed, although
microscopic examinations and cultures of sputum and subcutaneous abscess samples yielded negative results.
We considered this a paradoxical reaction similar to other reports in tuberculosis patients who had discontinued
biological agent treatments, and increased the dose of oral glucocorticoids. The patient’s symptoms gradually
improved with this increased dose and his lymph nodes and abscesses began to decrease in size.
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Conclusions: Clinicians should consider the possibility of a paradoxical response when the clinical manifestations of
non-tuberculosis mycobacteriosis worsen in spite of antimycobacterial therapy or after discontinuation of tumor
necrosis factor-α inhibitors. However, additional evidence is needed to verify our findings and to determine the
optimal management strategies for such cases.
Keywords: Non-tuberculosis mycobacteriosis, Mycobacterium intracellulare, Disseminated infection, Relapsing
polychondritis, Paradoxical response, Tumor necrosis factor-α inhibitor, Immune reconstitution inflammation
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Relapsing polychondritis (RP) is a rare systemic disorder
characterized by inflammation of the bilateral auricular
or tracheal cartilage. Standard treatments for RP include
immunosuppressive agents such as corticosteroids, bio-
logical agents such as tumor necrosis factor-α (TNF-α)
inhibitors and anti-inflammatory agents commonly used
to treat rheumatoid arthritis [1]. Patients receiving bio-
logical agents have an increased risk for opportunistic
mycobacterial and fungal infections [2]. In particular, pa-
tients with non-tuberculosis mycobacteriosis (NTM) in-
fections who receive treatments with biological agents are
more likely to develop extra-pulmonary or disseminated
infections compared with immunocompetent patients [3].
Although biological agents are contraindicated for pa-
tients with known NTM, it is difficult to completely elim-
inate the possibility of infection before starting therapy.
Furthermore, there have been reports of paradoxical
responses in patients who developed tuberculosis after
discontinuation of anti-TNF-α agents [4,5]. Here, we re-
port a case of disseminated NTM with RP caused by
TNF-α inhibitor therapy and a probable paradoxical re-
sponse to antimycobacterial therapy.
Case presentation
A 68-year-old man was referred to our hospital for a fever
of unknown origin. His medical history was unremarkable
except for hypertension. The presence of bilateral auricu-
laris and nasal root inflammation, along with auricular
perichondritis that was positive for anti-type II collagen
antibodies, led to a diagnosis of RP. Because he was refrac-
tory to prednisolone (PSL) glucocorticoid therapy at a
dose of 30 mg/day, adalimumab was initiated in combin-
ation with oral glucocorticoids after a chest computed
tomography (CT) scan indicated that he had no signs of
tuberculosis or NTM. Interferon-γ (IFN-γ) release assays
(T-SPOT. TB, Oxford Immunotec Ltd., Massachusetts,
US) and anti-Mycobacterium avium complex (MAC) anti-
body assays (Capilia MAC, TAUNS laboratories, Inc.,
Shizuoka, Japan) indicated also negative results. After
starting adalimumab treatment (40 mg), his clinical mani-
festations rapidly improved; therefore, adalimumab was
administered 3 times approximately every 2 weeks. Theclinical manifestations of RP resolved; moreover, while the
PSL dose was gradually tapered to 10 mg/day, treatment
with tacrolimus (1 mg/day) was introduced.
The patient subsequently exhibited an intermittent
high fever and productive cough 16 months after the RP
diagnosis. Laboratory tests showed a normal white blood
cell count (8,100/mm3) and procalcitonin concentration
(0.099 ng/mL), and increased C-reactive protein levels
(13.81 mg/dL, normal range < 0.3 mg/dL). The results of
all other laboratory tests including liver enzymes, creatin-
ine, and blood urea nitrogen were within normal ranges.
A chest CT scan showed granular shadows and multiple
nodules in both lung fields with mediastinal lymphaden-
opathy (Figure 1). Mycobacterium intracellulare was iso-
lated from 2 sputum samples; based on these findings, the
patient was diagnosed with a pulmonary infection with
this NTM. The minimum inhibitory concentrations of the
isolated strain for clarithromycin (CAM), rifampicin (RIF),
and ethambutol (EMB) were 0.5, 32.0, and 8.0 μg/mL,
respectively. Tacrolimus treatment was discontinued.
Treatments with CAM, RIF, and EMB at 800, 450, and
750 mg/day, respectively were initiated. The size of the
pulmonary nodules and mediastinal lymphadenopathy
increased 1 month after the initiation of antimycobac-
terial therapy. The high fever and general fatigue wors-
ened despite 4 months of treatment; paravertebral and
subcutaneous abscesses also developed and the size of
the mediastinal lymphadenopathy increased.
Because biopsy of the mediastinal lymphadenopathy
and a subcutaneous abscess of the right posterior thigh in-
dicated infection by M. intracellulare, the diagnosis of dis-
seminated MAC infection was confirmed. After 5 months
of antimycobacterial therapy with CAM, RIF, and EMB,
we changed the medication from RIF to rifabutin at
300 mg/day, increased the dose of CAM from 800 to
1,000 mg/day, and added streptomycin at 0.75 g, 3 times
per week; however, the abscesses continued to enlarge.
Tests for anti-human T-cell leukemia virus-1 antibodies,
anti-human immunodeficiency virus (HIV) antibodies,
and antibodies to IFN-γ all yielded negative results. Al-
though we slowly decreased the dose of PSL to 5 mg/day,
the mediastinal lymph nodes enlarged even further and
abscesses were formed. The mediastinal lymphadenopathy
Figure 1 Computed tomography images of disseminated NTM development. The white triangles indicate pulmonary nodules, mediastinal
lymph nodes, and paravertebral abscess.
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larged more and other subcutaneous abscesses developed,
although microscopic examination and culture results
of sputum and subcutaneous abscess samples indicated
negative results 9 months after induction of antimyco-
bacterial therapy. We considered this a paradoxical reac-
tion similar to that noted in previous reports in patients
with tuberculosis who discontinued biological agent ther-
apy; therefore, we increased the PSL dosage to 10 mg/day.
After this increase, his symptoms gradually improved and
the lymph nodes and abscesses began to decrease in size.
Due to the deterioration of RP symptoms, the PSL dosage
was increased to 30 mg/day and mizoribine was added as
a treatment; however, the MAC infection lesions contin-
ued to decrease in size. The clinical course, culture results,
treatment regimens, and CT scan images are shown seri-
ally in Figure 2.
Discussion and Conclusions
RP itself is not generally considered a risk factor for
mycobacterial infections since there have been no re-
ports of RP complicated with NTM. Reports in Thailand
and Taiwan found that that most non-HIV patients with
disseminated NTM infections exhibited positive results
for IFN-γ autoantibodies [6]; however, the patient in the
present case exhibited negative results for these anti-
bodies. Patients receiving biological agents are likely to
develop extra-pulmonary or disseminated NTM [3], and
several fetal cases have been reported [7-9]. Therefore,the disseminated NTM infection in this case was sus-
pected to be related to the use of a TNF α inhibitor.
Mori, et al. reviewed 13 pulmonary NTM cases that
had received biological therapy for RA, including inflixi-
mab, etanercept, adalimumab, and tocilizumab [10]. The
average time from the initiation of biological agent ther-
apy to development of NTM was 10 months (range:
6 weeks to 8.5 years), similar to our case (15 months).
Although no cases of disseminated NTM were reported,
most cases responded appropriate anti-NTM treatment
following discontinuation of biological agents, and none
of the cases had a paradoxical reaction after initiation of
anti-NTM treatment [10]. Furthermore, in one case,
restarting tocilizumab therapy while continuing anti-
NTM therapy resulted in a favorable outcome [10,11].
The paradoxical worsening of clinical symptoms and
radiologic findings despite effective antimycobacterial
therapy may be attributed to immune reconstitution in-
flammatory syndrome (IRIS). IRIS is defined as the wors-
ening or recurrence of inflammatory symptoms during
restoration of an effective immune response against path-
ogens of opportunistic infections [12,13]. The syndrome
has primarily been reported in patients infected with HIV
who experience immune reconstitution after initiation of
antiretroviral therapy.
It has been suggested that anti-TNF-α agents should
be discontinued when Mycobacterium tuberculosis infec-
tion occurs. However, IRIS has been reported in patients
with tuberculosis after discontinuation of anti-TNF-α
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Figure 2 Clinical course, microbiological test results, treatment regimens, and computed tomography images. The white triangles
indicate pulmonary nodules, mediastinal lymph nodes, paravertebral abscess, and subcutaneous abscess of the right posterior thigh.
Abbreviations: ADA, adalimumab; CAM, clarithromycin; EMB, ethambutol; PSL, prednisolone; RBT, rifabutin; RIF, rifampicin; SM, streptomycin;
TAC, tacrolimus.
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antimycobacterial drug therapy has been reported to be
effective in a tuberculosis case exhibiting a paradoxical re-
sponse [14]. There are no guidelines or sufficient evidence
to recommend a specific course of action in tuberculosis
patients administered TNF-α inhibitors who developed a
paradoxical response while receiving antimycobacterial
treatment.
The reasons for this paradoxical reaction to anti-NTM
treatment remain unclear. The combination of adalimu-
mab, tacrolimus, and prednisolone therapies might have
resulted in a high mycobacterial load that provoked an
immune/inflammatory response upon cessation of adali-
mumab and tacrolimus treatments.
To our knowledge, this is the first reported non-HIV
case of NTM to develop a paradoxical response. Al-
though we considered the presence of a paradoxical re-
sponse in the present case, the resumption of biological
agent treatment was risky because antimycobacterialtherapy against NTM is not always effective. Because
corticosteroids are an effective treatment for IRIS in
patients with HIV, we chose to increase the dose of PSL.
Fortunately, our patient responded to this increase, al-
though evidence regarding the optimal dose and dur-
ation of steroid therapy remains unclear.
If clinical manifestations of infection worsen despite
the administration of antimycobacterial therapy after
discontinuation of anti-TNF-α agents, the possibility of a
paradoxical response should be considered. Additional
evidence is needed to verify our findings and to deter-
mine optimal management of such cases.Consent
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